#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    White matter lesion Amyotrophic lateral sclerosis gene carrier Pulmonary alveolar haemorrhage Osteosarcoma recurrent B-cell lymphoma recurrent Chordoma B-cell type acute leukaemia Neuroblastoma Non-renal cell carcinoma of kidney Neuroendocrine carcinoma of the skin Neurofibroma Biliary cancer metastatic Squamous cell carcinoma of the cervix Eosinophilic granulomatosis with polyangiitis Endometrial cancer More trials…

    Learn about Rare Diseases

    Mantle cell lymphoma stage III – Basic Information Toxic epidermal necrolysis – Trials in Disease Ewing’s sarcoma – Diagnostics Myxofibrosarcoma – Basic Information Glomerulonephritis membranoproliferative – Life with Disease SAPHO syndrome – Basic Information Aicardi-Goutieres syndrome Alternating hemiplegia of childhood – Basic Information Ornithine transcarbamoylase deficiency – Basic Information Antisynthetase syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Aclidinium Bromide Sulodexide IHMA-2121771-1 Gskvx000000008866 Mk-1942 Brivaracetam Gsk4532990A Skb264 Amikacin Sulfate Sodium Chloride Solution 0.9% Golcadomide Mebeverine Hydrochloride PRT3789 PUCOTENLIMAB Roginolisib TUVATEXIB ANOC-001 Tobevibart Atl001 Tenofovir Alafenamide More therapies…

    Learn about Your Condition

    Muscular dystrophy Benign prostatic hyperplasia Paraesthesia Medication overuse headache Mixed dementia Colour blindness Multiple sclerosis relapse Glomerulonephritis acute Alagille syndrome Alveolar proteinosis Cervix carcinoma stage IV Breast cancer stage III Lung disorder Anal cancer stage II Compulsive sexual behaviour More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Fundacion CITA Alzheimer

Fundacion CITA Alzheimer

Pasealeku Mikeletegi 71, Donostia / San Sebastian, 20009, Spain

Want to learn more about this study or check if you can participate? Contact us.

  • Study of levetiracetam to prevent seizures in adults who have both Down syndrome and Alzheimer’s disease

    Recruiting

    3 1 1
    Investigated Diseases:
    • Trisomy 21
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • Levetiracetam
    Spain

  • Oral Semaglutide in People With Mild Cognitive Impairment or Mild Dementia of the Alzheimer’s Type

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Semaglutide
    Austria Belgium Bulgaria Czechia Denmark Finland +15

  • Study on the Effectiveness and Safety of GSK4527226 in Patients with Early Alzheimer’s Disease

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Florbetaben (18F)
    • Florbetapir (18F)
    • Florquinitau (18F)
    Finland France Germany Italy The Netherlands Norway +2

  • Study of BAN2401 (lecanemab) in people with early stage Alzheimer’s disease to evaluate its effectiveness in preventing disease progression

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Florquinitau (18F)
    • Flutafuranol (18F)
    • Lecanemab
    Spain

  • Study of Lecanemab (BAN2401) Treatment in People with Early Alzheimer’s Disease: Testing Safety and Effectiveness Over 18 Months

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Dementia Alzheimer’s type
    • Prodromal Alzheimer’s disease
    Investigated Drugs:
    • Lecanemab
    France Germany Italy Spain Sweden

  • Study of XPro1595 for Patients with Early Alzheimer’s Disease and Inflammation Markers

    Not recruiting

    2 1
    Investigated Diseases:
    • Dementia of the Alzheimer’s type uncomplicated
    Investigated Drugs:
    • Pegipanermin
    Czechia France Germany Poland Slovakia Spain

  • Study on the Long-term Safety and Effects of AL002 and Florquinitau F18 in Patients with Alzheimer’s Disease

    Not recruiting

    2 1
    Investigated Diseases:
    • Dementia Alzheimer’s type
    Investigated Drugs:
    • Florquinitau (18F)
    • Human Igg1 Monoclonal Antibody Against Trem2
    France Germany Italy The Netherlands Poland Spain

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!